Percorrer por data de Publicação, começado por "2025-09-19"
A mostrar 1 - 2 de 2
Resultados por página
Opções de ordenação
- Kinematic biomarkers of functional disability in older adultsPublication . Moreira, Juliana; Cunha, Bruno; Félix, José; Santos, Rubim; Sousa, Andreia S. P.; Santos Moreira, Juliana; Sousa Félix, José Manuel; Rubim Silva Santos, Manuel; Pinheiro de Sousa, Andreia SofiaThe Timed Up and Go (TUG) test is used to assess mobility in older adults, but its reliance on completion time limits its insight into detailed movement patterns that could serve as early indicators of functional decline. This study aimed to identify lower limb and trunk kinematic biomarkers during the TUG test that distinguish between older adults with and without functional disability, emphasizing the potential for wearable sensor applications. Sixty adults aged 60+ participated in this cross-sectional study. Three-dimensional lower limb and trunk range of motion (ROM), velocity, center of mass (CoM) displacement, and velocity were analyzed using an optoelectronic system across TUG subphases: sitto-walk, walk-forward, turn, walk-back, and turn-to-sit. Principal component analysis identified eleven principal components (PCs), explaining 84.33% of the total variance. PCs included sagittal hip and knee motion and CoM velocity during turn-to-sit and walking (PC1); tri-dimensional trunk velocity during turning, walk-back, and sit-to-walk transitions (PC2, PC4, PC6); sagittal knee and hip velocity in sit-to-walk (PC3); and frontal and transverse plane knee ROM and velocity during turning (PC5). Significant differences between functional disability groups were found for PC1 and PC4. These findings provide benchmark data for developing and validating wearable biosensors aimed at monitoring kinematic biomarkers.
- Deciphering the influence of CD276 glycode in colorectal cancer immunomodulationPublication . Magalhães, Mariana Moura; Peixoto, Andreia; Ferreira, José Alexandre; Santos, Lúcio Lara; Ferraz, RicardoColorectal cancer (CRC) remains a major contributor to cancer-related illness and death worlwide, with aggressive subtypes often resistant to conventional therapies. The imune checkpoint protein CD276 (B7-H3) is highly expressed in CRC and is associated with poor prognosis, tumor progression, and imune evasion. CD276 undergoes extensive glycosylation, a modification that influences protein stability, localisation, and imune interactions, yet the specific roles of its glycosylation in CRC are not well understood. This study examines how immature 0-glycosylation of CD276 affects CRC aggressiveness. To model the altered glycan landscape typical of cancer cells, C1GALT1-knockout CRC cells, which lack the enzyme necessary for 0-glycan elongation, were used. The effects of CD276 knockdown using small interfering RNA (siRNA) on cell proliferation and inasion were assessed by BrdU ELISA and Matrigel invasion assays, respectivily. Additionally, proteomic and phisphoproteomic analyses were conducted to explore how CD276 influences oncogenic signalling pathways. Our fundings reveal that aberrant, immature 0-glycosylation of CD276 promotes CRC cell proliferation and invasion by sustaining oncogenic biosynthetic and phosphorylation networks. Conversely, CD276 depletion activates stress responses involving RNA processing. DNA repair, and mitochondrial reorganisation, highlighting CD276 as a glycosylation-dependent driver of CRC aggressiveness and a potential therapuetic target.